
Alan Lyles

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11673044/publications.pdf Version: 2024-02-01



ALAN VIES

#	Article	lF	CITATIONS
1	An In-home Advanced Robotic System to Manage Elderly Home-care Patients' Medications: A Pilot Safety and Usability Study. Clinical Therapeutics, 2017, 39, 1054-1061.	2.5	49
2	Pharmaceutical Promotion in the United States. , 2016, , 231-251.		0
3	Handgrip strength and balance in older adults following withdrawal from long-term use of temazepam, zopiclone or zolpidem as hypnotics. BMC Geriatrics, 2014, 14, 121.	2.7	20
4	Melatonin for sedative withdrawal in older patients with primary insomnia: a randomized double-blind placebo-controlled trial. British Journal of Clinical Pharmacology, 2014, 77, 975-985.	2.4	33
5	Effect of withdrawal from long-term use of temazepam, zopiclone or zolpidem as hypnotic agents on cognition in older adults. European Journal of Clinical Pharmacology, 2014, 70, 319-329.	1.9	32
6	Content validation of a tool for assessing risks for drug-related problems to be used by practical nurses caring for home-dwelling clients aged ≥65Áyears: a Delphi survey. European Journal of Clinical Pharmacology, 2014, 70, 991-1002.	1.9	22
7	CNS Medications as Predictors of Precipitous Cognitive Decline in the Cognitively Disabled Aged: A Longitudinal Population-Based Study. Dementia and Geriatric Cognitive Disorders Extra, 2012, 2, 57-68.	1.3	26
8	Potentially Inappropriate Medication Use Among Finnish Non-Institutionalized People Aged ≥65 Years. Drugs and Aging, 2011, 28, 227-236.	2.7	39
9	Comparison of Prescribing Criteria to Evaluate the Appropriateness of Drug Treatment in Individuals Aged 65 and Older: A Systematic Review. Journal of the American Geriatrics Society, 2011, 59, 1521-1530.	2.6	162
10	Muted Incentives, Omitted Variables, and Pharmacoeconomic Validity: Two Strikes and You're Out!. Clinical Therapeutics, 2011, 33, 60-61.	2.5	0
11	National Versus International Generalizations from Cost-Effectiveness Analyses. Clinical Therapeutics, 2011, 33, 1444-1445.	2.5	Ο
12	The Relevance of International Studies to Informed Pharmacoeconomics and Health Policy Decisions. Clinical Therapeutics, 2010, 32, 106-107.	2.5	4
13	The Importance of Context to the Generalizability of International Research: The Other Health Care Reform. Clinical Therapeutics, 2010, 32, 2442-2443.	2.5	2
14	Health care reform: Is the process the outcome?. Clinical Therapeutics, 2009, 31, 2014-2017.	2.5	0
15	The symptom mitigation path of mobile community residents: Community pharmacy's role. Health Policy, 2009, 89, 14-25.	3.0	1
16	The prescribing continuum: Between prescription and over-the-counter drugs. Clinical Therapeutics, 2007, 29, 2244-2245.	2.5	3
17	Creating alternative incentives for pharmaceutical innovation. Clinical Therapeutics, 2006, 28, 126-128.	2.5	2
18	Hospitalization and Death Associated With Potentially Inappropriate Medication Prescriptions Among Elderly Nursing Home Residents. Archives of Internal Medicine, 2005, 165, 68.	3.8	357

Alan Lyles

#	Article	IF	CITATIONS
19	Must an interest be a conflict?. Clinical Therapeutics, 2005, 27, 344-345.	2.5	4
20	Potentially Inappropriate Medication Prescriptions among Elderly Nursing Home Residents: Their Scope and Associated Resident and Facility Characteristics. Health Services Research, 2004, 39, 1257-1276.	2.0	129
21	Evidence- or opinion-based pharmaceutical policy?. Clinical Therapeutics, 2004, 26, 1922-1923.	2.5	4
22	Pharmacy practice and health policy within the U.S., 2004, , 341-367.		0
23	Standards and certification to recognize pharmacoeconomics as a profession. Clinical Therapeutics, 2003, 25, 1004-1006.	2.5	5
24	Public-private partnerships at the national institutes of health: From discovery to commercialization. Clinical Therapeutics, 2003, 25, 2900-2902.	2.5	5
25	Achieving healthy people 2010 immunization goals: proceedings of a national conference. Chapel Hill, North Carolina: October 12-13, 2001. Background. Clinical Therapeutics, 2003, 25 Suppl A, A2-8.	2.5	0
26	Cost And Quality Trends In Direct Contracting Arrangements. Health Affairs, 2002, 21, 89-102.	5.2	9
27	Direct Marketing of Pharmaceuticals to Consumers. Annual Review of Public Health, 2002, 23, 73-91.	17.4	88
28	The Prescription Drug User Fee Act: Active Postmarketing Drug Surveillance and Safety. Clinical Therapeutics, 2002, 24, 800-802.	2.5	4
29	Improved medication use in long-term care: building on the consultant pharmacist's drug regimen review. American Journal of Managed Care, 2002, 8, 318-26.	1.1	10
30	AMCP Guidance for Submission of Clinical and Economic Evaluation Data to Support Formulary Listing in U.S. Health Plans and Pharmacy Benefits Management Organizations. Journal of Managed Care Pharmacy, 2001, 7, 272-282.	2.2	65
31	Use and Costs of Ambulatory Care Services Among Medicare Enrollees With Schizophrenia. Psychiatric Services, 2001, 52, 786-792.	2.0	40
32	Decision-makers′ use of pharmacoeconomics: what does the research tell us?. Expert Review of Pharmacoeconomics and Outcomes Research, 2001, 1, 133-144.	1.4	4
33	Services to Families of Adults With Schizophrenia: From Treatment Recommendations to Dissemination. Psychiatric Services, 1999, 50, 233-238.	2.0	141
34	Managed care pharmacy, socioeconomic assessments and drug adoption decisions. Social Science and Medicine, 1997, 45, 511-521.	3.8	43
35	A Comparison of Risk Factors in Juvenile-Onset and Adult-Onset Recurrent Respiratory Papillomatosis. Laryngoscope, 1992, 102, 9???13.	2.0	179